PURPOSE: In vivo evaluation of tamoxifen (TMX)-loaded folate-targeted nanoparticles prepared from a mixture of disulphide bond reduced bovine serum albumin (BSA-SH) and alginate-cysteine (ALG-CYS) as targeted delivery systems of TMX to tumour tissues. METHODS: TMX in solution, TMX included into folate-nanoparticles and their non-targeted analogues were intravenously administered to nude mice carrying xenograft MCF-7 tumours. The antitumor activity of these systems was characterized in terms of tumour growth rate, histological and immunohistochemical analysis of tumour tissues and TMX biodistribution. RESULTS: TMX-folate-attached nanoparticles caused tumour remission whereas free TMX or TMX-non-targeted nanoparticles could only stop the tumour development. The histological evaluation of tumour tissues showed that those treated with folate-conjugated systems presented the most quiescent and disorganized structures. Additionally, the lowest concentrations of TMX accumulated in non-targeted organs were also found after administration of the drug using this formulation. CONCLUSIONS: This study demonstrated that TMX-loaded folate-targeted systems were capable of reaching tumour sites, so enhancing the in vivo anticancer action of TMX, and allowing a new administration route to be applied and some of the current TMX therapy problems to be overcome.
PURPOSE: In vivo evaluation of tamoxifen (TMX)-loaded folate-targeted nanoparticles prepared from a mixture of disulphide bond reduced bovineserum albumin (BSA-SH) and alginate-cysteine (ALG-CYS) as targeted delivery systems of TMX to tumour tissues. METHODS:TMX in solution, TMX included into folate-nanoparticles and their non-targeted analogues were intravenously administered to nude mice carrying xenograft MCF-7 tumours. The antitumor activity of these systems was characterized in terms of tumour growth rate, histological and immunohistochemical analysis of tumour tissues and TMX biodistribution. RESULTS:TMX-folate-attached nanoparticles caused tumour remission whereas free TMX or TMX-non-targeted nanoparticles could only stop the tumour development. The histological evaluation of tumour tissues showed that those treated with folate-conjugated systems presented the most quiescent and disorganized structures. Additionally, the lowest concentrations of TMX accumulated in non-targeted organs were also found after administration of the drug using this formulation. CONCLUSIONS: This study demonstrated that TMX-loaded folate-targeted systems were capable of reaching tumour sites, so enhancing the in vivo anticancer action of TMX, and allowing a new administration route to be applied and some of the current TMX therapy problems to be overcome.
Authors: Mian M K Shahzad; Lingegowda S Mangala; Hee Dong Han; Chunhua Lu; Justin Bottsford-Miller; Masato Nishimura; Edna M Mora; Jeong-Won Lee; Rebecca L Stone; Chad V Pecot; Duangmani Thanapprapasr; Ju-Won Roh; Puja Gaur; Maya P Nair; Yun-Yong Park; Nirupama Sabnis; Michael T Deavers; Ju-Seog Lee; Lee M Ellis; Gabriel Lopez-Berestein; Walter J McConathy; Laszlo Prokai; Andras G Lacko; Anil K Sood Journal: Neoplasia Date: 2011-04 Impact factor: 5.715
Authors: Kyung-Hoon Lee; Bryan A Ward; Zeruesenay Desta; David A Flockhart; David R Jones Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-07-05 Impact factor: 3.205
Authors: María Inés Diaz Bessone; Lorena Simón-Gracia; Pablo Scodeller; María de Los Angeles Ramirez; María Amparo Lago Huvelle; Galo J A A Soler-Illia; Marina Simian Journal: J Nanobiotechnology Date: 2019-12-07 Impact factor: 10.435
Authors: Ana María Martínez-Relimpio; Marta Benito; Elena Pérez-Izquierdo; César Teijón; Rosa María Olmo; María Dolores Blanco Journal: Polymers (Basel) Date: 2021-06-24 Impact factor: 4.329